Semaglutide improves markers of cardiovascular risk in people with HIV.

AIDSMay 4, 2026 (epub)
Clinical ResearchEndocrinologyInfectious DiseasesCardiology

Jordan E Lake, Douglas W Kitch, Amy Kantor et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II clinical trial investigated the effects of semaglutide on cardiovascular risk markers in 36 adults with HIV and metabolic dysfunction. The study found that semaglutide significantly reduced triglycerides and CVD-linked lipoproteins, with 56% of participants showing improvement in the inflammatory marker GlycA. These findings suggest potential cardiovascular benefits from semaglutide beyond weight loss.

Key findings

  • Semaglutide reduced triglycerides and diglycerides, indicating improved lipid profiles.
  • 56% of participants with elevated GlycA improved, and 32% normalized.
  • CVD-linked lipoprotein species decreased, while LDL particle size increased.
  • Changes in lipoprotein/glycoprotein concentrations did not correlate with weight or insulin resistance.

Why it matters

Understanding the cardiovascular benefits of semaglutide in people with HIV and metabolic dysfunction is crucial, as it may offer new therapeutic avenues for managing cardiovascular risk in this population, independent of weight loss.

Source

PubMed · PMID 42084141

Published in AIDS. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.